Results 11 to 20 of about 9,340 (184)

Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven Diseases. [PDF]

Clin Pharmacol Ther
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Zecchin C, Schalkwijk S, Pouliquen IJ, Berges A, Bird N, Follows R, Austin D.   +6 more
europepmc   +2 more sources

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma

Frontiers in Pharmacology, 2023
Oral corticosteroids (OCS) are commonly used for the acute management of severe asthma exacerbations or as maintenance therapy; however, chronic use is associated with significant toxicities, e.g., osteoporosis. In the REal worlD Effectiveness and Safety
Christian Domingo, Christian Domingo, Ana Sogo, Ana Sogo, Enrique Casado, Eva Martínez-Moragón, Marina Blanco-Aparicio, Teresa Carrillo, Teresa Carrillo, David Bañas-Conejero, María-Guadalupe Sánchez-Herrero   +10 more
doaj   +1 more source

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype

Biomedicines, 2022
Severe asthma (SA) is categorized into multiple overlapping phenotypes and clinical characteristics driven by complex mechanistic inflammatory pathways. Mepolizumab is a human monoclonal antibody effectively targeting interleukin-5 in severe eosinophilic
Ruperto González-Pérez, Paloma Poza-Guedes, Elena Mederos-Luis, Inmaculada Sánchez-Machín   +3 more
doaj   +1 more source

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

Health Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj   +1 more source

Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study [PDF]

Laryngoscope Investig Otolaryngol
In the control group, 14% experienced at least one episode of ABRS. In the biologic‐exposed group, only 6% had an ABRS episode. This difference was shown to be statistically significant, reflecting a strong protective association biologics have on ABRS episodes.
Zheng W, Arslan M, Zhu C, Guirguis C, Spielman D.   +4 more
europepmc   +2 more sources

Use of Mepolizumab in Children and Adolescents with Asthma in the USA

Journal of Respiration, 2022
Introduction: Pediatric asthma affects 5.5 million US children and is the leading cause of pediatric chronic illness globally. Those with severe asthma have significantly higher healthcare costs compared to those with non-severe disease.
Jaclyn Davis, Pamela M. McMahon, Emily Welch, Cheryl McMahill-Walraven, Aziza Jamal-Allial, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S. Brown, Melissa Van Dyke, Ann Chen Wu   +11 more
doaj   +1 more source

Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan

Arthritis Research & Therapy, 2023
Objectives To investigate the efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) and factors contributing to glucocorticoid (GC) discontinuation.
Takashi Yamane, Akira Hashiramoto
doaj   +1 more source

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Frontiers in Immunology, 2023
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and ...
Santi Nolasco, Santi Nolasco, Andrea Portacci, Raffaele Campisi, Enrico Buonamico, Corrado Pelaia, Alida Benfante, Massimo Triggiani, Giuseppe Spadaro, Maria Filomena Caiaffa, Giulia Scioscia, Aikaterini Detoraki, Giuseppe Valenti, Francesco Papia, Alessandra Tomasello, Nunzio Crimi, Nicola Scichilone, Girolamo Pelaia, Giovanna Elisiana Carpagnano, Claudia Crimi, Claudia Crimi   +20 more
doaj   +1 more source

Response to mepolizumab treatment is sustained across 4-weekly dosing periods

ERJ Open Research, 2020
Background Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids,
Ian D. Pavord, Eugene R. Bleecker, Roland Buhl, Pascal Chanez, Elisabeth H. Bel, Peter Howarth, Daniel J. Bratton, Frank C. Albers, Steven Yancey   +8 more
doaj   +1 more source

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

New England Journal of Medicine, 2014
Ian D Pavord, Guy G Brusselle, Alfredo Chetta   +2 more
exaly   +2 more sources